Beranda › Karsinoma Sel Merkel
Uji klinis Karsinoma Sel Merkel yang merekrut di AS
24 studi untuk Karsinoma Sel Merkel merekrut peserta di lokasi di seluruh Amerika Serikat.
Kota dengan studi terbanyak
- Houston, TX6 studi
- Boston, MA5 studi
- Tampa, FL4 studi
- New York City, NY4 studi
- San Antonio, TX4 studi
- Seattle, WA3 studi
- Queens, NY3 studi
- Jacksonville, FL3 studi
- Arlington, VA3 studi
- Pittsburgh, PA3 studi
- Miami, FL3 studi
- Los Angeles, CA3 studi
- St. Louis, MO3 studi
- Washington, DC3 studi
- Nashville, TN3 studi
Berdasarkan negara bagian
- California5 studi
- Florida11 studi
- Maryland3 studi
- Massachusetts5 studi
- Michigan5 studi
- Missouri3 studi
- New Jersey3 studi
- New York4 studi
- North Carolina3 studi
- Pennsylvania4 studi
- Tennessee3 studi
- Texas8 studi
- Virginia3 studi
- Washington4 studi
Studi yang baru diperbarui
Teks studi resmi (Bahasa Inggris)
The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 30 Sep 2026 · NCT07285044Phase II Study of Peptide Receptor Radionuclide Therapy in Combination With Immunotherapy for Patients With Merkel Cell Cancer
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT05583708Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 24 Sep 2026 · NCT06047379Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors
Menerima pesertaFase 1
Usia 18 hingga 100 · Semua jenis kelamin · Diperbarui 22 Sep 2026 · NCT07006727Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors
Menerima pesertaFase 1/2
Usia 18 hingga 99 · Semua jenis kelamin · Diperbarui 22 Sep 2026 · NCT06814496Studies of Dermatologic Diseases Biospecimen Acquisition Protocol
Menerima pesertaStudi observasionalSukarelawan sehat diterima
1 Day – 100 Years · Semua jenis kelamin · Diperbarui 22 Sep 2026 · NCT02471352A Study of CRD3874-SI in People With Solid Tumors
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 21 Sep 2026 · NCT06021626Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 18 Sep 2026 · NCT05267626Cytotoxic T Lymphocytes in Treating Patients With Malignancies With BK and/or JC Virus
Menerima pesertaFase 2
Semua usia · Semua jenis kelamin · Diperbarui 4 Sep 2026 · NCT02479698Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 31 Agu 2026 · NCT05896839Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors
Menerima pesertaFase 1/2
Usia 16 ke atas · Semua jenis kelamin · Diperbarui 20 Agu 2026 · NCT05269381A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 19 Agu 2026 · NCT07115043A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 12 Agu 2026 · NCT05859074A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 11 Agu 2026 · NCT05592626A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 6 Agu 2026 · NCT07749586Hypofractionated Radiation Therapy for Merkel Cell Carcinoma
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 16 Jul 2026 · NCT05100095Neoadjuvant Cemiplimab in Newly Diagnosed or Recurrent Stage I-II Merkel Cell Carcinoma and Locoregionally Advanced Cutaneous Squamous Cell Carcinoma
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 25 Jun 2026 · NCT04975152MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 11 Jun 2026 · NCT05076760Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Carcinoma
Menerima pesertaFase 2/3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 17 Apr 2026 · NCT06947928EMLA Topical Cream for Treatment of Pain in Patients Receiving Intra-Dermal Technetium 99 Injections for Lymphoscintigraphy for Skin Cancers
Menerima pesertaFase 2
Usia 18 hingga 99 · Semua jenis kelamin · Diperbarui 10 Mar 2026 · NCT06223659Neoadjuvant PD-1 Blockade in Resectable Merkel Cell Carcinoma
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 18 Feb 2026 · NCT05496036TIL Therapy in cSCC and MCC
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 13 Feb 2026 · NCT07288073IFx-Hu2.0 As An Adjunctive Therapy To Pembrolizumab In Advanced Or Metastatic Merkel Cell Carcinoma (MCC)
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 15 Okt 2025 · NCT06940440A Beta-only IL-2 ImmunoTherapY Study
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 9 Jul 2025 · NCT05086692Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.